{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:09:54Z","timestamp":1793912994938,"version":"4.8.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015136","name":"UCSF Helen Diller Family Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102243","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:53:15Z","timestamp":1729277595000},"page":"102243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6841-968X","authenticated-orcid":false,"given":"S.N.","family":"Seyedin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-3783","authenticated-orcid":false,"given":"G.K.","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garemanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rafizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kaakour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4959-7652","authenticated-orcid":false,"given":"S.","family":"Dwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-5084","authenticated-orcid":false,"given":"A.","family":"Rezazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Daneshvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102243_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1254906","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?","volume":"13","author":"Maiorano","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102243_bib0002","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102243_bib0003","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102243_bib0004","doi-asserted-by":"crossref","first-page":"9533","DOI":"10.1038\/s41598-021-88952-8","article-title":"Palliative radiotherapy for gross hematuria in patients with advanced cancer","volume":"11","author":"Ogita","year":"2021","journal-title":"Sci Rep."},{"key":"10.1016\/j.clgc.2024.102243_bib0005","first-page":"e49936","article-title":"Durable response after combination therapy with enfortumab vedotin and radiotherapy in metastatic urothelial carcinoma: a report of two cases","volume":"15","author":"Ikarashi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.clgc.2024.102243_bib0006","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102243_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","article-title":"Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: a case series and review of the literature","volume":"43","author":"Khanjar","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clgc.2024.102243_bib0008","doi-asserted-by":"crossref","first-page":"k821","DOI":"10.1136\/bmj.k821","article-title":"Palliative radiotherapy","volume":"360","author":"Spencer","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2024.102243_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-020-0707-5","article-title":"Cancer-related fatigue: causes and current treatment options","volume":"21","author":"Thong","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clgc.2024.102243_bib0010","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/cancers16091649","article-title":"The safety and efficacy of the combination of sacituzumab govitecan and palliative radiotherapy-a retrospective multi-center cohort study","volume":"16","author":"Krug","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2024.102243_bib0011","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/0284186X.2021.1880025","article-title":"Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis","volume":"60","author":"Tey","year":"2021","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102243_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2024.03.013","article-title":"Activity of enfortumab vedotin and sacituzumab govitecan with radiation in preclinical models of bladder cancer","volume":"86","author":"Zhou","year":"2024","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:44:58Z","timestamp":1746463498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324002131"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102243","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102243"}}